https://prabadinews.com/
  • October 12, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Cemiplimab With Chemotherapy Sustains OS at 5 Years for Patients With Advanced NSCLC

Cemiplimab was also superior in improving progression-free survival, objective response rate, and duration of response in patients with non–small cell lung cancer (NSCLC).

administrator

Related Articles